Goto K, Fujii K, Onaka U, Abe I, Fujishima M
Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Hypertension. 2000 Oct;36(4):575-80. doi: 10.1161/01.hyp.36.4.575.
Angiotensin-converting enzyme (ACE) inhibitor improves the impaired hyperpolarization and relaxation to acetylcholine (ACh) via endothelium-derived hyperpolarizing factor (EDHF) in arteries of spontaneously hypertensive rats (SHR). We tested whether the angiotensin type 1 (AT(1)) receptor antagonist also improves EDHF-mediated responses and whether the combined AT(1) receptor blockade and ACE inhibition exert any additional effects. SHR were treated with either AT(1) receptor antagonist TCV-116 (5 mg. kg(-1). d(-1)) (SHR-T), enalapril (40 mg. kg(-1). d(-1)) (SHR-E), or their combination (SHR-T&E) from 8 to 11 months of age. Age-matched, untreated SHR (SHR-C) and Wistar Kyoto (WKY) rats served as controls (n=8 to 12 in each group). Three treatments lowered blood pressure comparably. EDHF-mediated hyperpolarization to ACh in mesenteric arteries in the absence or presence of norepinephrine was significantly improved in all treated SHR. In addition, the hyperpolarization in the presence of norepinephrine was significantly greater in SHR-T&E than in SHR-E (ACh 10(-5) mol/L with norepinephrine: SHR-C -7; SHR-T -19; SHR-E -15; SHR-T&E -22; WKY -14 mV). EDHF-mediated relaxation, assessed in the presence of indomethacin and N:(G)-nitro-L-arginine, was markedly improved in all treated SHR. Hyperpolarization and relaxation to levcromakalim, a direct opener of ATP-sensitive K(+)-channel, were similar in all groups. These findings suggest that AT(1) receptor antagonists are as effective as ACE inhibitors in improving EDHF-mediated responses in SHR. The beneficial effects of the combined AT(1) receptor blockade and ACE inhibition appears to be for the most part similar to those of each intervention.
血管紧张素转换酶(ACE)抑制剂可通过内皮衍生超极化因子(EDHF)改善自发性高血压大鼠(SHR)动脉中乙酰胆碱(ACh)诱导的超极化和舒张功能受损的情况。我们测试了血管紧张素1型(AT(1))受体拮抗剂是否也能改善EDHF介导的反应,以及联合使用AT(1)受体阻滞剂和ACE抑制剂是否会产生额外的效果。8至11月龄的SHR分别接受AT(1)受体拮抗剂TCV-116(5 mg·kg⁻¹·d⁻¹)(SHR-T)、依那普利(40 mg·kg⁻¹·d⁻¹)(SHR-E)或二者联合治疗(SHR-T&E)。年龄匹配的未治疗SHR(SHR-C)和Wistar Kyoto(WKY)大鼠作为对照(每组n = 8至12)。三种治疗方法降低血压的效果相当。在所有接受治疗的SHR中,无论是在有无去甲肾上腺素的情况下,EDHF介导的肠系膜动脉对ACh的超极化均显著改善。此外,SHR-T&E组在有去甲肾上腺素存在时的超极化程度显著高于SHR-E组(10⁻⁵ mol/L ACh与去甲肾上腺素:SHR-C -7;SHR-T -19;SHR-E -15;SHR-T&E -22;WKY -14 mV)。在吲哚美辛和N(G)-硝基-L-精氨酸存在的情况下评估的EDHF介导的舒张功能,在所有接受治疗的SHR中均显著改善。所有组对ATP敏感性钾通道的直接开放剂左旋克罗卡林的超极化和舒张反应相似。这些发现表明,AT(1)受体拮抗剂在改善SHR中EDHF介导的反应方面与ACE抑制剂同样有效。联合使用AT(1)受体阻滞剂和ACE抑制剂的有益效果在很大程度上与每种干预措施相似。